BRCA1 and breast carcinoma: While FDA guidelines indicate olaparib (AZD2281) and talazoparib for HER2-negative disease, the panel supports their use in any breast cancer subtype associated with germline BRCA1 or BRCA2 mutations 8,9 (NCCN guideline Ver.